
    
      The target population is composed of pre-menopausal women with symptomatic uterine myoma(s)
      characterised by heavy bleeding.The main objective of this study is to assess the sustained
      efficacy and safety of long term on-off treatment with PGL4001 5 or 10mg doses on uterine
      bleeding, myoma size, pain and quality of life.
    
  